Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Oscar Fernández, Miguel Angel Calleja-Hernández, José Meca-Lallana, Celia Oreja-Guevara, Ana Polanco & Ferran Pérez-Alcántara. (2017) Estimate of the cost of multiple sclerosis in Spain by literature review. Expert Review of Pharmacoeconomics & Outcomes Research 17:4, pages 321-333.
Read now
Read now
Joan Vidal, John Slof, David Serrano, Teresa Marqués, Hatice Kumru & Jesús Benito-Penalva. (2017) Cost-effectiveness of Intrathecal Baclofen Therapy in severe refractory non-focal disabling spasticity: a Spanish hospital perspective. Expert Review of Pharmacoeconomics & Outcomes Research 17:1, pages 67-76.
Read now
Read now
Adrien Gras & Julie Broughton. (2016) A cost-effectiveness model for the use of a cannabis-derived oromucosal spray for the treatment of spasticity in multiple sclerosis. Expert Review of Pharmacoeconomics & Outcomes Research 16:6, pages 771-779.
Read now
Read now
Sven G Meuth, Carlos Vila & Kerry L Dechant. (2015) Effect of Sativex on spasticity-associated symptoms in patients with multiple sclerosis. Expert Review of Neurotherapeutics 15:8, pages 909-918.
Read now
Read now
John Slof, Leonardo Ruiz & Carlos Vila. (2015) Cost-effectiveness of Sativex in multiple sclerosis spasticity: new data and application to Italy. Expert Review of Pharmacoeconomics & Outcomes Research 15:3, pages 379-391.
Read now
Read now
Ralf Gold. (2013) Multiple sclerosis spasticity management – key publications. Expert Review of Neurotherapeutics 13:sup2, pages 47-48.
Read now
Read now
Nicolas Collongues & Patrick Vermersch. (2013) Multiple sclerosis spasticity: ‘state-of-the-art’ questionnaire survey of specialized healthcare professionals. Expert Review of Neurotherapeutics 13:sup1, pages 21-25.
Read now
Read now
Peter Flachenecker. (2013) A new multiple sclerosis spasticity treatment option: effect in everyday clinical practice and cost–effectiveness in Germany. Expert Review of Neurotherapeutics 13:sup1, pages 15-19.
Read now
Read now
Articles from other publishers (18)
Daniel Erku, Shakti Shrestha & Paul Scuffham. (2021) Cost-Effectiveness of Medicinal Cannabis for Management of Refractory Symptoms Associated With Chronic Conditions: A Systematic Review of Economic Evaluations. Value in Health 24:10, pages 1520-1530.
Crossref
Crossref
Mark Oppe, Daniela Ortín-Sulbarán, Carlos Vila Silván, Anabel Estévez-Carrillo & Juan M. Ramos-Goñi. (2021) Cost-effectiveness of adding Sativex® spray to spasticity care in Belgium: using bootstrapping instead of Monte Carlo simulation for probabilistic sensitivity analyses. The European Journal of Health Economics 22:5, pages 711-721.
Crossref
Crossref
Christopher Vannabouathong, Meng Zhu, Yaping Chang & Mohit Bhandari. (2021) Can Medical Cannabis Therapies be Cost-Effective in the Non-Surgical Management of Chronic Knee Pain?. Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders 14, pages 117954412110024.
Crossref
Crossref
Anna Mokrova, Susanna Sologova & Victoria Ignatyeva. (2020) Modelling expenses for multiple sclerosis treatment. Farmacevticheskoe delo i tehnologija lekarstv (Pharmacy and Pharmaceutical Technology):3, pages 11-34.
Crossref
Crossref
Andrew J Palmer, Ingrid van der Mei, Bruce V Taylor, Philip M Clarke, Steve SimpsonJrJr & Hasnat Ahmad. (2019) Modelling the impact of multiple sclerosis on life expectancy, quality-adjusted life years and total lifetime costs: Evidence from Australia. Multiple Sclerosis Journal 26:4, pages 411-420.
Crossref
Crossref
Lorenzo G. Mantovani, Paolo Cozzolino, Paolo A. Cortesi & Francesco Patti. (2020) Cost-Effectiveness Analysis of Cannabinoid Oromucosal Spray Use for the Management of Spasticity in Subjects with Multiple Sclerosis. Clinical Drug Investigation 40:4, pages 319-326.
Crossref
Crossref
Griffin A. TyreeReith SarkarBrandon K. BellowsRonald J. EllisJoseph Hampton AtkinsonThomas D. MarcotteMark S. WallaceIgor GrantYuyan ShiJames D. MurphyDavid J. Grelotti. (2019) A Cost-Effectiveness Model for Adjunctive Smoked Cannabis in the Treatment of Chronic Neuropathic Pain. Cannabis and Cannabinoid Research 4:1, pages 62-72.
Crossref
Crossref
Elaine Nguyen, Craig I. Coleman, Christine G. Kohn & Erin R. Weeda. (2018) Ranolazine in patients with type 2 diabetes and chronic angina: A cost-effectiveness analysis and assessment of health-related quality-of-life. International Journal of Cardiology 273, pages 34-38.
Crossref
Crossref
Samuel Herzog, Marian Shanahan, Peter Grimison, Anh Tran, Nicole Wong, Nicholas Lintzeris, John Simes, Martin Stockler & Rachael L. Morton. (2017) Systematic Review of the Costs and Benefits of Prescribed Cannabis-Based Medicines for the Management of Chronic Illness: Lessons from Multiple Sclerosis. PharmacoEconomics 36:1, pages 67-78.
Crossref
Crossref
Steven M. Bailey & Claire M. Rice. 2018. Progressive Multiple Sclerosis. Progressive Multiple Sclerosis
155
205
.
Gillian M. Keating. (2017) Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray (Sativex®): A Review in Multiple Sclerosis-Related Spasticity. Drugs 77:5, pages 563-574.
Crossref
Crossref
Uwe K. Zettl, Paulus Rommer, Petra Hipp & Robert Patejdl. (2015) Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis. Therapeutic Advances in Neurological Disorders 9:1, pages 9-30.
Crossref
Crossref
Ludwig Kappos & Franz Fazekas. (2015) What is new in MS spasticity research? Poster session highlights. Neurodegenerative Disease Management 5:6s, pages 27-30.
Crossref
Crossref
Craig I Coleman, Nick Freemantle & Christine G Kohn. (2015) Ranolazine for the treatment of chronic stable angina: a cost-effectiveness analysis from the UK perspective. BMJ Open 5:11, pages e008861.
Crossref
Crossref
VL Stevenson, A Gras, JI Bárdos & J Broughton. (2015) The high cost of spasticity in multiple sclerosis to individuals and society. Multiple Sclerosis Journal 21:12, pages 1583-1592.
Crossref
Crossref
William G. Notcutt. (2015) Clinical Use of Cannabinoids for Symptom Control in Multiple Sclerosis. Neurotherapeutics 12:4, pages 769-777.
Crossref
Crossref
Christine G. Kohn, Matthew W. Parker, Brendan L. Limone & Craig I. Coleman. (2014) Cost-Effectiveness of Ranolazine Added to Standard-of-Care Treatment in Patients With Chronic Stable Angina Pectoris. The American Journal of Cardiology 113:8, pages 1306-1311.
Crossref
Crossref
Yahiya Y. Syed, Kate McKeage & Lesley J. Scott. (2014) Delta-9-Tetrahydrocannabinol/Cannabidiol (Sativex®): A Review of Its Use in Patients with Moderate to Severe Spasticity Due to Multiple Sclerosis. Drugs 74:5, pages 563-578.
Crossref
Crossref